Form 4: Seres Therapeutics Insider Trades: DesRosier Acquires and Sells Stock

Thomas DesRosier, EVP and Chief Legal Officer at Seres Therapeutics, Inc., reported transactions involving the acquisition and sale of common stock, including those related to restricted stock units.

Summary

• Thomas DesRosier, EVP and Chief Legal Officer of Seres Therapeutics, Inc., engaged in stock transactions on May 15, 2026, and May 18, 2026.
• On May 15, 2026, 244 shares of common stock were acquired, increasing beneficial ownership to 8,033 shares.
• On May 18, 2026, 79 shares of common stock were sold at a price of $7.53 per share, resulting in beneficial ownership of 7,954 shares.
• The transactions also involved restricted stock units (RSUs). On May 15, 2026, 133 RSUs were acquired, and 111 RSUs were acquired, contributing to a total of 398 and 779 RSUs respectively.
• The sales were executed under a Rule 10b5-1 trading plan established on March 2, 2023, intended to cover tax obligations arising from the vesting of RSUs.
• Specific details regarding the vesting schedules of RSUs are provided, with some having vested and others set to vest in quarterly installments.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports routine insider transactions related to compensation and tax obligations under a pre-established plan, with no significant strategic or financial performance indicators.

Positives

• Acquisition of 244 shares of common stock on May 15, 2026, indicating continued investment or compensation.
• Acquisition of restricted stock units, suggesting ongoing equity-based compensation and alignment with company performance.
• The sale of shares was conducted under a pre-established Rule 10b5-1 plan, demonstrating adherence to compliance and risk management strategies for insider trading.
• The stated purpose of the sale is to cover tax obligations, a common and legitimate reason for insider stock sales.

Negatives

• A net decrease in directly held common stock from 8,033 to 7,954 shares following the reported transactions.
• The sale of 79 shares, even if for tax purposes, represents a reduction in direct beneficial ownership.

Risks

• The vesting and settlement of restricted stock units, while a form of compensation, can lead to increased selling pressure on the stock if a significant portion of vested units are sold.
• The reliance on Rule 10b5-1 plans, while compliant, can be subject to market volatility and the timing of vesting and tax obligations.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
• The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter.
• The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of Rule 10b5-1 plans by executives like Thomas DesRosier is common practice to manage personal stock sales in a compliant manner, particularly for tax obligations related to equity compensation.

Stakeholder Impact

• Shareholders: The transactions represent a minor adjustment in insider holdings and are executed under a compliant plan, thus unlikely to have a significant immediate impact on share price or market perception.

Next Steps

• Continued vesting and settlement of remaining restricted stock units in quarterly installments.
• Potential future sales of common stock by Thomas DesRosier under the Rule 10b5-1 plan to cover ongoing tax obligations.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Seres Therapeutics, MCRB, Stock Transaction, Restricted Stock Units, Rule 10b5-1, Beneficial Ownership, Thomas DesRosier